文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗在罕见黑色素瘤亚型中的安全性与疗效:CheckMate 172 研究

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
PubMed 文献 · Eur J Cancer · 2019-08-21

CheckMate 172 是一项 II 期单臂开放标签多中心研究,评估纳武利尤单抗在伊匹木单抗进展后的晚期黑色素瘤患者中的安全性与疗效。1008 例患者中,非肢端皮肤型 723 例、眼型 103 例、黏膜型 63 例、肢端皮肤型 55 例、其他亚型 64 例。各亚型 ≥3 级治疗相关选择性不良事件发生率无显著差异,眼型和黏膜型总生存期较短。

要点

  • 纳武利尤单抗在伊匹木单抗进展后各黑色素瘤亚型中安全性相似。
  • 肢端皮肤型与非肢端皮肤型总生存期相近,眼型和黏膜型较差。
  • 眼型中位 OS 12.6 个月,黏膜型 11.5 个月,均低于皮肤型。

核心结论

  • 纳武利尤单抗在伊匹木单抗进展后的安全性在各黑色素瘤亚型间相似。
  • 肢端皮肤型与非肢端皮肤型生存结局相似,眼型和黏膜型中位总生存期较低。

研究设计与样本

  • CheckMate 172 为 II 期、单臂、开放标签、多中心研究。
  • 纳入伊匹木单抗治疗进展后或之后的晚期黑色素瘤患者,共 1008 例接受治疗。
  • 患者接受纳武利尤单抗 3 mg/kg 每 2 周一次,最长 2 年。
  • 主要终点为 ≥3 级治疗相关选择性不良事件发生率。

主要发现

  • 非肢端皮肤型 723 例(71.7%),眼型 103 例(10.2%),黏膜型 63 例(6.3%),肢端皮肤型 55 例(5.5%),其他亚型 64 例(6.3%)。
  • 各亚型间及与总人群相比,≥3 级治疗相关选择性不良事件发生率无有意义的差异。
  • 未出现新的安全性信号。
  • 中位随访至少 18 个月时,非肢端皮肤型中位总生存期 25.3 个月,18 个月总生存率 57.5%。
  • 肢端皮肤型中位总生存期 25.8 个月,18 个月总生存率 59.0%。

关键数值与推荐

  • 纳武利尤单抗剂量为 3 mg/kg,每 2 周一次,最长 2 年。
  • 主要终点为 ≥3 级治疗相关选择性不良事件发生率。

临床怎么用

  • 伊匹木单抗进展后的晚期黑色素瘤患者可考虑纳武利尤单抗,各亚型安全性相似。
  • 眼型和黏膜型黑色素瘤患者接受纳武利尤单抗时预后较差,需更密切监测。

局限性

  • 单臂设计,无对照组。
  • 各亚型样本量差异较大,眼型 103 例、黏膜型 63 例、肢端皮肤型 55 例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nivolumab has been widely studied in non-acral cutaneous melanoma; however, limited data are available in other melanoma subtypes. We report outcomes by melanoma subtype in patients who received nivolumab after progression on prior ipilimumab. PATIENTS AND METHODS: CheckMate 172 was a phase II, single-arm, open-label, multicentre study that evaluated nivolumab in patients with advanced melanoma who progressed on or after ipilimumab. Patients received 3 mg/kg of nivolumab, every 2 weeks for up to 2 years. The primary end-point was incidence of grade ≥3, treatment-related select adverse events (AEs). RESULTS: Among 1008 treated patients, we report data on patients with non-acral cutaneous melanoma (n = 723 [71.7%]), ocular melanoma (n = 103 [10.2%]), mucosal melanoma (n = 63 [6.3%]), acral cutaneous melanoma (n = 55 [5.5%]) and other melanoma subtypes (n = 64 [6.3%]). There were no meaningful differences in the incidence of grade ≥3, treatment-related select AEs among melanoma subtypes or compared with the total population. No new safety signals emerged. At a minimum follow-up of 18 months, median overall survival was 25.3 months for non-acral cutaneous melanoma and 25.8 months for acral cutaneous melanoma, with 18-month overall survival rates of 57.5% and 59.0%, respectively. Median overall survival was 12.6 months for ocular melanoma and 11.5 months for mucosal melanoma, with 18-month overall survival rates of 34.8% and 31.5%, respectively. CONCLUSIONS: The safety profile of nivolumab after ipilimumab is similar across melanoma subtypes. Compared with non-acral cutaneous melanoma, patients with acral cutaneous melanoma had similar survival outcomes, whereas those with ocular and mucosal melanoma had lower median overall survival. CLINICALTRIALS. GOV ID: NCT02156804.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019. PMID: 31445199. doi:10.1016/j.ejca.2019.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。